The Living Heart project is a global project of XNUMXD human heart simulation that enables virtual research and development of breakthrough treatments.
- The project expanded to 95 partners worldwide
- The simulation now makes it possible to examine the effect of drugs on heart activity
- The project supports the FDA's effort to promote the use of simulation and modeling within the 21 initiativest Century Cures Act
Dassault Systèmes presented at the 3DEXPERIENCE North America forum the milestones reached by a project
"The Living Heart", The simulation of the human heart in 3D for the purposes of treatment, diagnosis and prevention of heart diseases. The simulation allows the scientific and medical community to locate innovative treatments to improve treatment in faster and more targeted ways. With the announcement that the simulation will also be available in the cloud, based on Dassault Systèmes' XNUMXDEXPERIENCE platform, thus making it more accessible to researchers and medical professionals. Even the smallest medical device companies can quickly use the application on demand, to perform virtual tests, while minimizing infrastructure costs. The move will also enable the operation of Living Heart inside treatment rooms.
"Medical devices are required to pass thousands of tests already in the development stages," said Joe Promicola, president and senior engineer, Kleenex. "With the transition of "The Living Heart" to the cloud, we can perform an unlimited number of tests efficiently and simultaneously for new designs, instead of one test at a time. In doing so, we significantly remove the path to innovation, not to mention time and costs."
Dassault Systèmes also announced that, for the first time, the Living Heart project was used to simulate in detail the interaction of drugs that affect heart function. Researchers at Stanford University working with UberCloud made use of Living Heart To create a model that will allow medical companies to examine the risk of drugs causing arrhythmias Heart - the main reason for rejection of approvals from the FDA.
Since signing a 2014-year agreement with the FDA in 5, Dassault Systèmes has continued to work in cooperation with the regulatory body to promote the use of simulation and models - as a way to speed up approvals of medical devices and drugs.
"Modeling and simulation play a vital role in the organization of diverse data sets and in the research of alternative and diverse programs. This allows new, effective and safe treatments to progress more quickly through the various stages of clinical trials," said FDA Commissioner Dr. Scott Gottlieb in July 2017 , when he announced the FDA's plan to promote the availability of medical innovation to the consumer.
The Living Heart counts more than 95 partnerships worldwide that include collaborations with researchers, doctors, device manufacturers and regulatory bodies, united under the mission to promote open innovation and face challenges in the development of medical treatments. The project supports 15 studies by providing access to the model, the technologies related to it and the expertise gained in the project. To date, 8 articles have been published in scientific magazines dealing with the innovative use of the model and the subject of safety and efficiency in the development of medical devices.
"The Living Heart project is a strategic part of Dassault Systèmes' broader effort to leverage its advanced simulation applications to push the boundaries of science," said Jan Columbel, Vice President Life Sciences, Dassault Systèmes. "By combining community creation and a revolutionary platform, we are starting to see the results of a project Living Heart applied to expand the research of the heart, as well as for other parts of the human body, such as the brain, the spinal cord, the leg and the eye, with the aim of reaching new worlds of medical care."
